Body Composition and Adipose Tissue in HIV

NCT ID: NCT03226821

Last Updated: 2025-05-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-02-07
• Study Completion Date: 2025-04-30

Brief Summary

In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of tesamorelin therapy of patients with HIV lipodystrophy. Subjects will do body composition testing, adipose tissue biopsy, metabolic rate measurements and insulin sensitivity assessment before, 6 and 12 months after daily injections of tesamorelin 2 mg by subcutaneous injection.

Detailed Description

HIV lipodystrophy is increasingly recognized as a common and clinically significant long-term sequelae of HIV treatment. In the HIV lipodystrophy lipohypertrophy phenotype, visceral adipose tissue (VAT) is increased and this is associated with reduced growth hormone (GH) secretion. Mounting evidence also links this phenotype with dyslipidemia, insulin resistance, subclinical atherosclerosis and cardiovascular (CV) disease in patients with HIV disease. The etiology of HIV lipodystrophy (HIVLD) with central adiposity is unclear, but this phenotype is increasingly common with newer, less lipotoxic combination anti-retroviral therapy (cART) use. VAT and hepatic lipid accumulation, are important health concerns for HIVLD patients. This body composition pattern may contribute to the increased cardiovascular risk that has been demonstrated in patients with HIV lipodystrophy. Patients with HIVLD and central adiposity have been shown to have reduced GH secretion. Thus, a medication has been developed to augment GH secretion. This medication is tesamorelin. GH supplementation in other clinical settings has been shown to reduce visceral adiposity and may reduce hepatic lipid content.

Conditions

HIV Lipodystrophy Syndrome; Growth Hormone Deficiency; Body Composition

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Tesamorelin

Subjects will be treated with tesamorelin 2 mg by subcutaneous injection daily. Enrolled subjects will have 6 visits - a baseline visit before starting tesamorelin, a visit at 1 month, 3 months, 6 months, 9 months and at 1 year of tesamorelin (GHRH analogue) therapy. Blood sampling for safety labs and clinical examinations will be performed at each visit.

Group Type: EXPERIMENTAL

Tesamorelin

Intervention Type: DRUG

Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily

Interventions

Tesamorelin

Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily

Intervention Type: DRUG

Other Intervention Names

Egrifta

Eligibility Criteria

Inclusion Criteria

• HIV-infected subjects with HIV lipodystrophy (HIVLD)
• Abdominal fat accumulation defined as: Waist Circumference (WC) 102 cm for men, 88 cm for women, except in subjects of East/South Asian ethnicity in whom this will be defined by WC 90 cm for men and 80 cm for women.
• Weight stable for 8 weeks prior to enrollment,
• CD4 count >100 cells/mm3
• HIV RNA load <1000 copies/mL
• Fasting plasma glucose <120 mg/dL
• Stable combination anti-retroviral therapy (cART) of any regimen for ≥ 8 weeks prior to study enrollment

Exclusion Criteria

• Diabetes mellitus requiring medication
• History of any malignancy
• Abnormal renal or liver function
• Pregnancy or women of childbearing age who are not using an acceptable means of contraception
• History disorder of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism or pituitary tumor/surgery
• Head irradiation or head trauma or adrenal insufficiency
• Systemic glucocorticoid use
• Known hypersensitivity to tesamorelin and/or mannitol

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 68 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

Sponsor Role: collaborator

Columbia University

OTHER

Sponsor Role: lead

Responsible Party

Pamela U. Freda

Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Pamela U. Freda, MD

Role: PRINCIPAL_INVESTIGATOR

Columbia University

Locations

Neuroendocrine Unit and Pituitary Center, Columbia University

New York, New York, United States

Countries

United States

Other Identifiers

R01DK110771

Identifier Type: NIH

Identifier Source: secondary_id

View Link

AAAR2634

Identifier Type: -

Identifier Source: org_study_id